{
    "2018-01-10": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018",
                "features": {
                    "keywords": [
                        "Perjeta",
                        "Roche",
                        "Revenue Growth",
                        "2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Novartis becomes latest big-name collaborator for Chapel Hill company",
                "features": {
                    "keywords": [
                        "Novartis",
                        "collaborator",
                        "Chapel Hill"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Merck's Keytruda Combo Gets Breakthrough Therapy Status",
                "features": {
                    "keywords": [
                        "Merck",
                        "Keytruda",
                        "Breakthrough Therapy"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Trial",
                        "Psoriasis",
                        "Cosentyx",
                        "Biosimilar"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Ignyta and Its Key Risks in 2018",
                "features": {
                    "keywords": [
                        "Ignyta",
                        "Risks",
                        "2018"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Imbruvica",
                        "Foundation Therapy",
                        "Hematologic Oncology"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Inside Ignyta’s Financial Performance",
                "features": {
                    "keywords": [
                        "Ignyta",
                        "Financial Performance"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "The Swiss Stock Market Pulled Back From Yesterday's New High",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Pulled Back",
                        "Yesterday's New High"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}